Atlas Trials

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

Clinical trial NCT01262352 · COMPLETED

Trial details

NCT number
NCT01262352
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2011-01-01
Primary completion
2011-11-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.